These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 380803)

  • 1. Phase II study of VM-26 in acute leukemia, neuroblastoma, and other refractory childhood malignancies: a report from the Children's Cancer Study Group.
    Bleyer WA; Krivit W; Chard RL; Hammond D
    Cancer Treat Rep; 1979 Jun; 63(6):977-81. PubMed ID: 380803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of VP-16-213 in childhood malignant disease: a Children's Cancer Study Group Report.
    Chard RL; Krivit W; Bleyer WA; Hammond D
    Cancer Treat Rep; 1979; 63(11-12):1755-9. PubMed ID: 294306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epipodophyllotoxin VM-26 in the treatment of childhood neuroblastoma.
    Rivera G; Green A; Hayes A; Avery T; Pratt C
    Cancer Treat Rep; 1977 Oct; 61(7):1243-8. PubMed ID: 589594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I-II trial of VM-26 (NSC-122819) in the treatment of children with late-stage leukemia.
    Rosenstock JG; Donaldson MH
    Cancer Treat Rep; 1976 Mar; 60(3):265-7. PubMed ID: 1063066
    [No Abstract]   [Full Text] [Related]  

  • 5. VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group Study (EST 1474).
    Chiuten DF; Bennett JM; Creech RH; Glick J; Falkson G; Brodovsky HS; Begg CB; Muggia FM; Carbone PP
    Cancer Treat Rep; 1979 Jan; 63(1):7-11. PubMed ID: 369693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allergic reactions to teniposide in patients with neuroblastoma and lymphoid malignancies.
    Hayes FA; Abromowitch M; Green AA
    Cancer Treat Rep; 1985 Apr; 69(4):439-41. PubMed ID: 3857970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose teniposide for refractory malignancies: a phase I study.
    de Vries EG; Mulder NH; Postmus PE; Vriesendorp R; Willemse PH; Sleijfer DT
    Cancer Treat Rep; 1986 May; 70(5):595-8. PubMed ID: 3708608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
    Blaney SM; Needle MN; Gillespie A; Sato JK; Reaman GH; Berg SL; Adamson PC; Krailo MD; Bleyer WA; Poplack DG; Balis FM
    Clin Cancer Res; 1998 Feb; 4(2):357-60. PubMed ID: 9516923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II evaluation of teniposide and ifosfamide in refractory adult acute lymphocytic leukemia: a Southwest Oncology Group Study.
    Ryan DH; Kopecky KJ; Head D; Gumbart CN; Grever MR; Karanes C; Weick JK; Coltman CA
    Cancer Treat Rep; 1987; 71(7-8):713-6. PubMed ID: 3475171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teniposide: a review of 12 years of experience.
    O'Dwyer PJ; Alonso MT; Leyland-Jones B; Marsoni S
    Cancer Treat Rep; 1984 Dec; 68(12):1455-66. PubMed ID: 6391663
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.
    Radice PA; Bunn PA; Ihde DC
    Cancer Treat Rep; 1979 Aug; 63(8):1231-9. PubMed ID: 225026
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial.
    Rodman JH; Abromowitch M; Sinkule JA; Hayes FA; Rivera GK; Evans WE
    J Clin Oncol; 1987 Jul; 5(7):1007-14. PubMed ID: 3598607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of neocarzinostatin in children with cancer.
    Rivera G; Howarth C; Aur RJ; Pratt CB
    Cancer Treat Rep; 1978 Dec; 62(12):2105-7. PubMed ID: 156067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [VP 16-213 in the treatment of acute leukemia in childhood].
    Esumi N; Arakawa S; Imashuku S
    Gan To Kagaku Ryoho; 1983 Mar; 10(3):848-51. PubMed ID: 6576730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4'-demethylepipodophyllotoxin 9-(4,6-o-2-thenylidene-beta-D-glucopyranoside) (NSC-122819; VM-26) and 4'-demethylepipodophyllotoxin 9-(4.6-0-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213) in childhood cancer: preliminary observations.
    Rivera G; Avery T; Pratt C
    Cancer Chemother Rep; 1975; 59(4):743-9. PubMed ID: 1100225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trail cisplatin in refractory childhood cancer: Children's Cancer Study Group Report.
    Baum ES; Gaynon P; Greenberg L; Krivit W; Hammond D
    Cancer Treat Rep; 1981; 65(9-10):815-22. PubMed ID: 6944156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of prednimustine in children with recurrent cancer: a Children's Cancer Study Group report.
    Gaynon PS; Baum ES; Krivit W; Hammond D
    Cancer Treat Rep; 1982 Jul; 66(7):1583-4. PubMed ID: 6284362
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase I clinical evaluation of diaziquone in childhood cancer.
    Ettinger LJ; Siegel SE; Belasco JB; Evans AE; Ruccione KS; Jamin DC; Rohrbaugh TM; Higgins GR
    Cancer Treat Rep; 1985 Mar; 69(3):323-7. PubMed ID: 3856480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Phase II study of NK 171 (etoposide) on malignant lymphomas and acute leukemia. A cooperative study group on NK 171 in hematological malignancies].
    Kimura K; Yamada K; Yoshida T
    Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):496-501. PubMed ID: 3954373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isophosphamide therapy for hematologic malignancies in patients refractory to prior treatment.
    Rodriguez V; McCredie KB; Keating MJ; Valdivieso M; Bodey GP; Freireich EJ
    Cancer Treat Rep; 1978 Apr; 62(4):493-7. PubMed ID: 350386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.